H.C. Wainwright Lowers Liquidia Price Target to $58 Following Patent Ruling

H.C. Wainwright has lowered its price target for Liquidia Technologies (LQDA) to $58 from $130. This follows a court ruling that found the company infringed on United Therapeutics patents. The firm maintains a Buy rating on the stock, citing the potential for the company's Yutrepia treatment to capture market share in pulmonary arterial hypertension (PAH).

"The most likely near-term outcome is a 'skinny label' for the drug with PH-ILD removed during the appeals process," analysts at H.C. Wainwright stated in a note to clients.

Impact on Financial Modeling

The price target adjustment stems from the removal of the pulmonary hypertension associated with interstitial lung disease (PH-ILD) indication from the firm's financial model. This change follows a legal decision confirming that Liquidia infringed on patents held by United Therapeutics regarding inhaled treprostinil. By excluding the PH-ILD indication, analysts are recalibrating their revenue projections to account for the ongoing legal and regulatory uncertainty surrounding the drug's label.

H.C. Wainwright maintains a long-term outlook for Yutrepia. The firm projects that the drug could reach $1.1 billion in peak sales for the PAH indication by 2030, provided the company navigates the current appeals process.

Market Reaction and Valuation

Liquidia’s shares declined 59% over the past week to $27.99. H.C. Wainwright characterized this sell-off as an overreaction, noting that the current share price sits below the InvestingPro fair value estimate of $34.75.

Understanding 'Skinny Labeling'

In the pharmaceutical industry, a "skinny label" refers to a strategy where a manufacturer seeks FDA approval for a drug while omitting specific indications or uses that are protected by another company's patents. This allows the firm to market the drug for the remaining, non-infringing indications. For Liquidia, the strategy involves proceeding with the PAH indication while the legal dispute over the PH-ILD indication continues through the court system.